[Evaluation of plasma renin activity in acute myocardial infarction patients treated with primary percutaneous

Piotr J Stryjewski1, Artur Z Pietrucha, Katarzyna Stopyra

  • 1Oddział Kardiologii i Chorób Wewnetrznych Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie. pstryjewski@o2.pl

Przeglad Lekarski
|October 21, 2011
PubMed

Insights

Plasma renin activity (PRA) levels fluctuate in the early stages following ST-segment elevation myocardial infarction (STEMI), peaking between 5 days and 1 month. Initial PRA is notably higher in men than women after STEMI treated with primary PCI.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biochemistry

Context:

  • Acute ST-segment elevation myocardial infarction (STEMI) is a critical cardiovascular event.
  • Primary percutaneous coronary intervention (PCI) is a standard treatment for STEMI.
  • The role of the renin-angiotensin-aldosterone system (RAAS) in post-MI recovery is of significant interest.

Purpose:

  • To evaluate plasma renin activity (PRA) changes in patients with STEMI treated with primary PCI.
  • To compare PRA levels between men and women post-STEMI.
  • To investigate correlations between PRA and clinical/biochemical parameters.

Summary:

  • PRA levels were monitored in 40 STEMI patients (30 men, 10 women) treated with primary PCI.
  • PRA showed dynamic changes, peaking between 5 days and 1 month post-STEMI.
  • Significantly higher PRA was observed in men compared to women on day 1 post-STEMI, with no significant differences thereafter.
  • No significant correlations were found between PRA and age, BMI, NTproBNP, hsCRP, lipids, or left ventricular function.

Impact:

  • This study highlights the temporal dynamics of PRA in the acute phase of STEMI.
  • Findings suggest a potential sex-specific difference in early RAAS activation post-STEMI.
  • Understanding PRA changes may offer insights into myocardial recovery and risk stratification.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...